When Ben Sasse announced last December that he had been diagnosed with Stage 4 pancreatic cancer, he called it a death ...

MALVERN, Pa., March 23, 2026 (GLOBE NEWSWIRE)-- Ocugen, Inc. (“Ocugen” or the “Company”) (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced ...

Morgans healthcare analyst Iain Wilkie highlights seven ASX companies with upcoming catalysts in 2026. ... Read More The post ...

The MarketWatch News Department was not involved in the creation of this content. Real-world case study webinar demonstrates how AI-powered site identification and automated feasibility outreach ...

Climb Bio, Inc. (Nasdaq: CLYM), a clinical-stage biotechnology company developing therapeutics for immune-mediated diseases, today announced details for the next installment of their R&D Spotlight ...

Confirmed, pooled, blinded COVID-19 events in the ongoing Phase 3 DECLARATION study of VYD2311 accumulated to date (~ 50% of study progress) can ...

April 1, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company") today announced that a Phase II Clinical Trial of ...

Join the “New Developments in PCNSL Treatment” webinar to learn about new research, clinical trials, specialists, ...

Despite measurable gains, the Greek pharma industry warns the country's clinical trial ecosystem still needs stronger ...

Net revenue increase of 5% in Q4 2025 vs. Q3 2025Jaguar received an up-front payment of $16Mof non-dilutive capital in ...

To Host April 9 Investor Briefing Featuring Live Demo Of Withzeta.Ai Platform. Lantern Pharma (NASDAQ: LTRN) announced it will host an investor, analyst and shareholder briefing on April 9, 2026, at 8 ...